Document YjD1GeM4MLq88a7eRwN2Bw3wE

AR226-2771 FOR DU FONT DSE ONLY Copies Co: Haakell B. I. du Poat de Iteaours & Co., Inc. Laboratory for lexicology and Industrial Elkton Boad, P. 0. Box 50 Newark, Delaware 19/11 Medicine HASKELL LaBOBAIOK? 8ZPC2I NO. 593-81 Material Tested Octanoic acid, pentadecafluoro", aaaaoaiuB a alt* Haskell No. 14,045 & 12,037 Other Codes C-8 Study Initiated/Completed 5/18/81-6/9/81 Material Submitted by Polyer Products Department Washington Works AMMONIUM PERFLUOROOCTAMOATE BLOOD LEVELS IN THE FEMALE BAT SUMMARY; To evaluate toe ove "all health implications of the various biological effects produced >y ouaoniua perfluorooctanoate (C-8), a series of studies was undertaken to measure C-8 levels in whole blood as a function of a number of variables including route of administration, time following administration, and number oi treatments* Most work has been conducted in the male rat but possible tesatogenic effects of C-8 led to extending this work to the female rat and particularly to the pregnant rat. The uptake and clearance of C-8 from the blood of female rats following a single oJ. dose was rapid, wich the peak reached 1-2 hours post-treatment and with virtual total clearance by 24 hours. A dose-response was demonstrated with no apparent changes in blood C-8 levels following multiple oral dosing. The slower clearance rate in male rats was demonstrated following a single oral dose. The same general statements apply following inhalation exposure* A single 6-hour inhalation exposure resulted in peak blood levels within 1 hour after cessation of exposure, the material rapidly cleared from the blood, the auaber of exposures did not affect blood.levels, and male rats cleared the compound much oore slowly. Pregnant and non-pregnant rats showed similar C-8 blood levels following either oral or inhalation exposures. 1 - Company Sanitized. Doss not conla'n TSCA CBI The aoount of C-8 present as che straight chain isoner increases relative to the non-straight chain isomers as the ciae following C-8 administration increasa. This suggests that the non-straight chain isoaers are cleared from the blood o^re rapidly than the straight chain isomer or chat a aecabolite is present* INTRODUCTION; In evaluating the biological effects "<: -mmonium perfluorooctanoate (C-8). the basic animal modelhas ->n the male albino Crl:CD* rat (subacute dermal toxicity.pBBIHBK^ suoacute inhalation coxicicy^l----l^f^landCflf1^ and acute oral toxicity 0----1. In the subacute studies, blood Leve^s^f C-8 were determined to obtain correlations with biological effects. Metabolic work at 3M Company and at Baskell Laboratory^--------Moss degu&astrsted a distinct difference in che excretory rate of C-8 in male and female rats; tha female rat clears the compound via urinary excretion rapidly (alithin 24 hours) while the male rat excreted the compound more slowly. As a result, circulating levels of C-8, as measured by blood levels, are considerably higher in male rats. Tec, in spite of this difference in handling C-8, the acute effects of C-8 in the rat are similar (L 950 values, liver enlargement as a function of dose). Becent evidence of a teratogenic effect of C-8 in the rat were reported by 3M Company (Oral jBLangFeinder Study of T-2998 CoC in Pregnant Bats, Report (M-601, March 12', 1981) leading to different concern for the safety of women of childbearihg age in the workplace. This series of studies was undertaken to measure blood C-8 levels in female (and malea for reference purposes) rats as a function of the following variables: ^ I -a) funcdtirooin of post-exposure time following oral administration b) multiple versus silgle doses c) function of post-eipoeure time inhalation exposure response characteristics -a) comparison of levels, pregnant versus noil-pregnant rats b) oral exposure and inhalation exposure PROCEDURE: A. Animals Female albino rats, approximately 7-8 weeks old and weighing approximately 200 g; pregnant primigravida females weighing approximately 200 g, and male rats, approximately B weeks old and weighing approximately 250 g, were all supplied by the Charles River Breeding Laboratories, Inc. (Crl:CD, (^-jwpn-sy Ssn^^8^' u'' ;.;o^ c&i'tts';*"- "i'SCfa OBI North Viloiogton, MA). The rats were housed 2/cage in 8" x 8" x 14" suspended, atalnless-steel wire-oesh cages and allowed food (Purina Certified Rodent Chow 15002, Ralscon Purina Coapnay, St. Louis, Ho) and water ad libitua. The rats (with the exception of those received as pregnant froa the supplier) were observed for general suitability for 1 week prior to testing. B. Conpound Administration For oral treatoent, the material was adainistered via gavage as aqueous solutions (0.03-2.OX). Inhalation exposures were conducted by generating the appropriate dust atoosphere. Air was passed through a 2-atage glass generator with an electric surface vibrator agitating the first stage to prevent buildup on apparatus:walls. Bacs were exposed whole-body in 150 L glass and stainless steel chabers. Each exposure was 6 hours. Chaaber concentrations were determined both gravlaetrically (drawing known voluaes of chaaber air through preweigh^d Gelaan glass fiber filters. Type AE, 25 aa at 2 L/ainute and calculating the concentration froa weight gain on the filters/L of chaaber air saailed) and analytically (spectrophotoaetric by dissolving C-8 froa the fild&rs into acidified aqueous aethylene blue solution, extracting the colored coaplex into chlorofora, and reading at 627.6 na against standards prepared daily). C, Blood Sagples Blood saaples were obtained froa each rat by cardiac puncture, whole blood saaples were refrigerated and subaitted to PPD for cheaical analysis to determine C-6^concentracion ISM Appendix A, Decerainacion Perfluorooctanoace in Bed Blood,(^Analytical Beport Dated 9/16/81). P. Outline of Experiaental Groups M\ T---- ^----> Group A Dose 25 ag/kg orally, 3 feaale rats per group, sacrificed A j. 1/4 hour after dosing A-2 1/2 hour after dosing A-3 1 hour after dosing A-4 2 hours after dosing A-5 4 hours after dosing A-6 8 hours after dosing A-7 24 hours after dosing Group B B-l B-2 B-3 B-4 Dose 2*5 ag/kg orally, 3 feaale rats per group, sacrificed 1/2 hour after dosing 2 hours after dosing 8 hours after dosing 24 hours after dosing - 3 - ncesnolco^alnTSCACBl impany Saniti. zed,. DC8-' "u , Group C Dose 150 og/kg orally, 3 feaale cats per group, sacrificed C-l 1/2 hour after dosing C-2 2 hours after doaing C-3 8 hours after dosing C-4 24 hours after dosing Group D Dose 11 day with 25 eg/leg orally each day, 3 female rats per group, than sacrificed D-l D-2 D-3 D-4 D-5 D-6 D-7 Group B B-l E-2 B-3 E-4 11//<4 1I//:2 2 4 8 24 168 hour after llth dose hour after llth dose hours after llth dose hours after llth dose hours after llth dose hours after llth dose hours after lleh doae Ooae 25 og/lif orally, 3 aale rats per group, sacrificed 1/2 hour after dosing 8 hour* after doaing 24 hours after doaing 168 hours after doaing I- ^ Group ? Exposure via inhalation, 6 hr/day, 10 ag/a Ees&ale rata per group, sacrificed single exposure, 3 F-l 1/4 hour after exposure F-2 1/2 hour after exposure F-3 1 hour after exposure F-4 2 haurii after exposure r-5 4 hours after exposure F-6 a howrt after exposure F-7 24 hours 'after txposure F-8 168 hours after exposure (p G Exposure via Inhalation, 6 hr/day, 1 og/a , single exposure, 3 fonale rats per group, sacrificed G-l 1/2 hour after exposure G-2 2 hours aftsr exposure G-3 8 hours after exposure G-4 24 hours after exposure 4 - ^B^-.^^^^^ Group H 3 Exposure via inhalation, 6 hr/day, 0.1 ag/n , single exposure, 3 feaale rats per group, sacrificed H-l 1/2 hour after exposure H-2 2 hours after exposure B-3 8 hours after exposure H-4 24 hours after exposure Group I Exposure via inhalation, 6 hr/day, 10 ng/n , single exposure, 3 male rats per group, cicrificed 1-1 1/2 hour after exposure 1-2 2 hours after exposure 1-3 8 hours after exposure 1-4 24 hours after exposure Group J Dose 25 og/kg orally, gestation day 15, 3 pregnant rats per group, sacrificed J-l 1/2 hour after dosing J-2 2 hours after dosing J-3 8 hours after dosing J-4 24 hours after dosing Group K Dose 25 og/kg/d^y orally, gestation days 6 through 11, 3 pregnant rats per group, sacrificed K-l 1/2 hours after 6th dose K-2 2 hours acer 6th dose Group ^ Dose 25 og/Kg/day orally, gestation days 6 through 15, 3 pregnant rats per group, sacrificed L-l 1/2 hour after 10th dose L-2 2 hours after 10th dose L-3 8 hours after 10th dose L-4 24 bours After 10th dose Group M Exposure via inhalation, 6 hr/day, 10 ag/a , single exposure, gestation day 15, 3 pregnant rats per group sacrificed M-l 1/2 hour after exposure M-2 2 hours after exposure - 5 - .o^8^50^031 . nocsn01" ;on^ny S^ camlUSQ'-' Group H Exposure via inhalation, 6 br/day, 10 mg/n , gestation days 6 through IS, 3 pregnant rats par group, sacrifice H-l 1/2 hour after 10th exposure RESULTS AM) CONCLDSIOHS Besults of the anaoniua perfluorooetanoate levels in rac blood are presented in the Table* Included in the cable are the C-8 blood levels as well as the percent atraigbt-cha^n C-8. The variables considered and results obtained are discussed below: o Oral adoiniscration, feaale rats, C-8 levels as a function of dine post-dosing (see Figure 1) C-8 levels of 14 ppa were seen 15 minutes following the dose (25 ag/kg) These levels rose to a peak of approximately 30 ppa at 1 to 2 hours, dropped to 26 ppa by 8 hours, and to 0.7 and 0*045 ppa at 24 and 168 hours respectively. Conclude: C-8 is absorbed and rapidly cleared from the blood of feaale rats given a single oral dose. o Oral adainistxation, feaale rats, C-8 levels as a function of dose (aee Figure 2) C-8 levels at 1/2 hour following treatment ranged froa 3 to 162 ppa, doses adainistered 2.5 to 150 ag/kg. The ssae dose response was seen at 24 fhours with blood values ranging froa 0.12 (2.5 g/kg) to 18 (150 ag/tsg) ppa. The response was linear. * Conclude: C-8 in blood is directly related to the asount of C-8 administered orally* o Oral administration, male and feaale rats following a single oral dose of. 25 og/kg (see Figure 3) C-8 levels in feaale rats were 16 ppc (1/2 hour), 26 ppa (8 hours), 0*7 ppa (24 hours), and 0.045 ppa (168 hours). The corresponding values for oale rats were 23, 63, 50, and 23 ppa. Conclude; C-8 is retained in the blood of male rats to a greater extent than feaale rats following oral treatment. o Oral administration, feaale rats, C-8 levels as a function of number of doses (Figure 4) Blood levels in feaale rats given 1 versus 11 oral doses of C-8 were not considerably different. Concentrations at 1/4 hours post-treatment were 14 and 17 ppm, 1 and 11 doses respectively. company Sanitized. Doas not conla'n TSCA CB1 At 1/2 hour C-8 concentrationa were 16 and 25 ppa; at 8 hours, 26 and 13 ppa; at 24 hours, 0.7 and 0.8 ppu; and at 168 hours, 0.045 and 0.10 ppa, 1 and 11 doses respectively. Conclude: C-8 does not appear to accusulate In the blood of feaale rats following repeated oral treatment. The nuaber of treataents does not seea to Influence the C-8 blood level with dose reaaining constant. o Inhalation exposures, feaali rats, C-8 levels as a function of tiae poat-exposare (sea Figure 5) C-8 levels of 96 ppa were seen 15 oinutes following a single 6hour inhalation exposure to 10 ag/a This level stayed around 100-110 ppa through 1 hour, fell to approziaately 70 ppa 8 hours, further decreased to 52 ppa at 24 hours, and dropped to 0.39 ppa 168 hours later.: This saae general pattern was seen in rats exposed to either 0.1 or 1 ag/a . The lag phase seen in oral exposures is not, seen here due to blood sampling following a 6-hour inhalation exposure (rather than a single oral dose at a given, finite tiae). Conclude: C-8 is absorbed and rapidly cleared froa the blood of feaale rats given single 6-hour inhalation exposure. o Inhalation exposures, feaale rats, C-8 levels as a function of dose (see Figure 5) C-8 levels at 1/2 hour following a singles-hour Inhalation exposure ranged |croa 2 to 100 ppa airborne concentrations of 0.1 to 10 ag/a Th^ saae dose response was seen at 2 hours (2, 17, 69 ppa), 8 hours (0.85, 4. 71 ppa) and 24 hours (0.14, 0.56, 52 ppa) - concentrations corresponding to 0.1, 1, and 10 ag/a The response is linear at 1/2 hour (correlation coefficient of 0.999). Conclude: C-8 in blood is directly related to the aaount of C-8 inhaled. At the highest level used, the clearance rate is soaewhac slower than seen at the lower levels. This suggests aassive overload^ in the clearance system. o Inhalation exposures,aale and feaale rats following a single 6 hour inhalation of 10 ag/a . (Table, Groups F and I) C-8 levels in feaale rats were 109 ppa (1/2 hour), 69 ppa (2 hours), 71 ppa (8 hours), and 52 ppa (24 hours). The corresponding values for sale rat.. were 137, 157, 182, and 147 ppa. - 7 - Company Sanitized. Does not contain TSCA CB Conclude: C-8 ia retained in the blood of male rats co a greater extent than feaale rats following inhalation exposure. o Oral adainiateration to pregnant and non-pregnant feaale rats, C-8 levels foiloHiag a single oral dose (figure 6) C-8 levels in both pregnant and aon-pregnant rats following a single 25 og/teg oral dose were essentially the sane (16 and 10 ppa) at 1/2 hour, 33 and 39 ppa at 2 nours, 26 and 31 pptt at 8 hours, non-pregnant and pregnant rats respectively. Conclude: C-8 clearance following oral dosing is not altered in pregnant vs. aon-pregnant rats* o Inhalation and oral creaciaenc, pregnant rats, C-8 levels as a function of moaber of doses (Table, Groups J, R, L. M, and N) Blood levels in pregnant rats given either 1, 6 or 10 doses of C-8 ware essentially the saae 1/2 and 24 hours following the last oral cceacac&c* 'At 1/2 hour the levels were 18, 12, and 12 ppa, 1, 6, and 10 creacaents respectively. When comparing the levels seen at 2 and 8 Nours following a series of 10 consecutive doses, there appears to be a lowering of C-8 blood concentrations in the rats given 10 doaes (IS coBpaxed to 25 ppa at 2 hours, 11 coapaxed to 31 at; 8 hours). This oay indicate an enhanced clearance of C-8 with multiple dosing but would require conformation prior to acceptance as fact. Blood levels following 1 or 10 consecutive 6 hours/day inhalation exposures were not different. Conclude: C-8 does not appear to aceuaulace in the blood of pregnant rats following repeated oral or inhalation exposures. o The relative aaount of straight-chain C-8 increases as the tiae foli'ving the last exposure to C-8 increases. The data obtained from rats given a single oral dose of 25 og/kg deaonstrates this with straight-chain C-8 being 76-78X, 1/4 to 1/2 hour following treatment and 91Z, 4 and 8 hour^ following treatment. Following inhalation exposure, feaale rats tend to have a relatively high percent" of straight-chain C-8 (around 902) 1/4 hour after exposure* This probably reflects the point-in-tine sample collected reaeabering chat the rat has been Inhaling C-8 for 6 hours prior to being sampled at various times post-exposure* In oale rats, the clearance of non-straight chain C-8 is apparently slower with 73-872 being straight-chain froa 1/2 co 168 hours post-oral exposure and 76-822 straight-chain 1/2 to 24 hours post-inhalation exposure* Conclude: Non-straight chain C-8 is apparently cleared from the blood more rapidly than straight chain. The clearance rates for non-straight chain C-8 is more rapid in feaale rats. conWnTSCA GDI Company Sanity, oo.o no. * Syqonyaa; o Auoniua perfluorooctanoate Work conducted by: R^ZI , C^ ^^^-y^' i--JohJonhn E. Henry / Technician ^4^). 7 ^ .^Stephen D. Naah ' ^ rT-e-ct-h_n^ic^i-a_n ^ ^ ^^" '-Clarence W. Butt Teebolcian Work Supervised by: Study Director/Report Prepared by : / Bfirtie ^l Burgess ^ ^ L A i ^ ItesearchCEoxicologis^ . 0."Louis Dashiell Supervisor GLK:tac:WP:4.6 ^ -3 Date Issued; December 7, 1981 ..port Ho. 593-81 Company Sanitized. Does not contain TSCA CB1  ^ 0 "> ' ^ ^ co ^ ^ ^ 0 o, w :; 0 1K 0 0 5 H3". -^ (/ 0 > 0 a TABLE Group Sex Route of Administration A-l P A-2 F A-3 F A-4 F A-5 V f A-6 i ? A-7 I ? A-8 I P B-l F B-2 F B-3 F B-4 F C-l P C-2 F C-3 P C-4 F D-l P D-2 F D-3 F D-4 F Oral Oral Oral Oral Oral Oral Oral Oral Oral Oral Oral Oral Oral Oral Oral Oral Oral Oral Oral Oral C-8 Doae , (mg/kg) (ag/n ) Blood Level in Lata Number of Doses or Exposures Saaple taken (hours following last dose/exposure) C-8 Blood Level (pp) Mean Rangae 25 25 25 25 25 25 25 5&SJ 2.5 2.5 2.5 2.5 150 150 150 150 25 25 25 25 1/4 14 9-16 1/2 16(2) 16 1 31 29-33 2 33 27-37 4 23 17-27 26 26-29 24 0.7 0.4-1.2 168 0.045 0.033-0.05 C 1/2 3(2) 2-3 2 NA " NA -- 24 0.12(2) 0.11-0.13 1/2 162 102-223 2 NA 8 157 131-178 24 18(2) 15-20 11 1/4 17 10-24 11 1/2 25 22-29 11 2 NA NA 11 Group Sex Route of Administration Dose (ng/kg) D-5 F OOrraall 2255 DD--67 FF Oral 25 E-l M Oral 25 25 E-2 H Oral 2S KE--43 HH OOpraall 25 P l 0 0 3 ^ F-l F P-2 F F-3 F P-4 F F-5 F Br -f0t F P-7 P F-8 F Inh. Inh. . Inh. Inh. Inh. Inh. Inh. Inh. ^ G-l F 5: G-2 F S G"3 F t. G-4 F 0 . H-l F ^ H-2 F S. H-3 F S H-4 F 1. 5 -^ y> 0 y 0 9 Inh. Inh. Inh. Inh. Inh. Inh. Inh. Inh. TABLE (Cont.) Humher of Saaple taken C-8 Blood Level Str ) B3-) DEoKecepeosourres 1 (ahsotudrsoafeo/ellxopwoianugre ) Mean (ppn Range 13 9-18 11 24 0.76 0.67-0.81 11 0.10 0,06-0.12 11 168 l 1/2 23 1 6Ji ..I... . - . . ...... . .... ..-24-....-..-...... .-50 - .. 1 . .,, .. . . 168 23 17-28 62-66 45-5315-28 10 1 10 1 10 1 10 1 10 10 10 10 1/4 1/2 1 2 4 24 168 96 109 113 0/.7a 0f7t 71 52 0.39 80-121 93-124 104-121 50-79 60-77 43-111 42-68 0.11-0.54 1/2 7 6-9 1 2 17 10-24 1 4 3-6 1 24 0.56 0.24-0.79 1 1/2 2 1-2 0.1 2 2 1-2 0.1 0.85 0.76-0.99 0.1 24 0.14 0.10-0.16 0.1 TABLE (Cont.) Group fiex Route of Ad ministration Dose ,, (ng/kg) <Bg/a>) 1? t 3 .K. 5 . $ 3; % ? 0 0 0 w. b " S ^<" Mb . -m l 0 > Q s 1-1 M 1-2 M 1-3 H 1-4 H J=l . J-2 J-3 J-4 pgg- PgF PgF PgF K"1 PgF K-2 PgF L-l PgF L-2 PgP L-3 PgF L-4 PgF M-l PgF M-2 PgF N-l PgF Control P Inh. Inh. Inh. Inh. --Awowojl -- - .- --...... 25- Oral 25 Oral 25 Oral 25 Oral 25 Oral 25 Oral 25 Oral 25 Oral 25 Oral 25 Inh. Inh. Inh. - - 10 10 10 10 --" 10 10 10 - 1Number of 1Doses or 1Exposures Snaple taken C-8 Blood Level (lioikirs followirig (ppaa) last dose/exposiare) Mean Range 1 1 1 1 - . .....^......-.-.. 1 1 1 6 6 10 10 10 10 1 1 10 - 1/2 2 24 ^ 2 8 24 1/2 2 1/2 2 8 24 1/2 2 1/2 137 118-163 157 114-203 182 170-198 147 143-151 - 18 39 31 2 14-21 34-44 29-33 2 12 5-16 37 28-35 12 9-15 15 11-17 11 9-13 1 1-2 77 66-91 90 86-96 53 45-67 0.-.0..0.08 0.0-008 FIGbHE C-8 BLOOD LEVELS AS A FUNCTION OF TIME POST-ORAL POSING IN FEMALE RATS TIME  FIGURE 2 C-8 BOLROAOLD DLOESVEELTSO AFSEMAALFEUNRCATTISON OF &UBdul00 ,, oo^ys30 .9oaa--M^S po^osi^" -ST- C~8 BLOOD LEVELS IN PPM 0 -* s) W *. m o 0> 0 0000^^ ^, "J c n 00 B f 0 s^ s^ Z H Of01 1> 53 I M M in z 0 M Ziwfe 0_ > tB-1P^1 tJ ?s f 0 ' q 05 0 f) to > ia c^ CO I CD  1C? -i--r i ' i I FIGURE 4 C-8 BLNOUOMDBELREVOEFLSDOASSESA TOFUNRACTTSION OF i 111111" Q- 0. z 101 ^ </) -i^jj 1 L S o u> ' w % 9- 0 0 ^ o txl ^j 0 0 0 i --J mLLJ I m I 0 -4 W 0 > 0 01 1C? 10-' ir)2 I----i----i yio"1 LKOKMDi D-1 ORAL A-tO ORAL i i i 11-- itf | I ' t * '-- 101 TIME FIGUh. C-8 BLOOD LEVELS AS A FUNCTION OF TIME FOLLOWING INHALATION EXPOSURE TO FEMALE RATS -T--T TIME ^K) 30 VOS1 uieuo3 cu seoQ parnues Auadmoo -8T- C-8 BLOOD LEVELS IN PPM o, ^ " 0. 0. 1--I 1111 -I--I Oo I 11 III 0-. <=^ i i iiiii|----i--r-rr D o ft OB cs CD 0 IE; ''3 f "a M I 5 0 ?gz" ^5 Cft ,z i3 ?^ "' ' ' "'"'----i--i i \ mil APPENDIX A 3> (I'UlftMllMl E. 1. DU FONT DE NEMOURS & COMPANY MCOttWMHTtO WiLMINGTON. DELAWARE 19898 POLYMER PNOOUCTS OEPARTMCNT CXFCniMmTAL. TAT10N A."AmiCAL REPORT cc: -'. September 16, 1981 DETERMINATION OP PERFUJOROOCTAMOATEIH RAT BLOOD (Job Mo. 812-666,812-667 , PRAL NOB. 81-2047-2057.81-2122-2193.81-2281-2286, 81-2288-2290.81-2295-2305,81-2323-2330.81-2334-2341.81-2344-2363,81-2368. 81-2U3-2472.81-2497-2513.81-2523-2527.81-2550-2552.81-2594-2598; Aa pare of studio 181 rac blood samples submit1 octanoate (03). (The remaining but noc analyzed at this tio). WIVS. to 19isamples ,and fl79/] fr - M exposure of rats ;en analyzed for peYrfflluuoro^been dried for storage Tha analyses were done ujsing the gas chromatographic procedure described in a previous report (letter of 1/26/81). Details are given in Table 1. As noted there, the results are given in ppm F for comparison with total organic fluorine analyses and represent overall Cg concentration (straight-chain and 4 branched isoners). For most of the samples! percent straight-chain Cg was also calculated as described earli'-r, and is Included in the tables. . Results and sample identification for the three studies are given in the attached tables as follows. Table 1 Table 2;' Tables Table 5; Tables 6 Table 8;1 Tables 9f submitted by L. Dashiell) unples submitted by J. Hamill) |(0ral) arranged by group and averages for each set of samples. amples^submitted by rranged by _time, w < BBrtdnhala^ion, Samples submitted byp--------r| HBrranged by group and recovery time. ^ 4 ^ S. S. Stafford Attachments jah Key Words: Perfluorooctanoate, ^ ^Sl^od Analysis. (SfimpanSyanitizsci. Does not contain TSCA Ct^ -19- Thert's a world of things we're doing something about  hj 0 f S. ^ ^ ^ 1, 0) 3 ^ > 0 5 - Sample (a) PRAL No. 81-2047 81-2048 81-2049 81-2050 81-2051 81-2052 ,81-2170 81-21TI ^ 81-2172 81-2173 81-2174 81-2175 81-2176 81-2177 81-2178 81-2179 81-2130 81-2131 81-2182 81-2133 81-2184 TABLE I PRRFLUOKOOCTANOAItT) ERAT BLOOD SAMPLES CONCENTRATION OF Date Received 5/15/81 5/15/81 5/15/31 5/15/81 5/15/81 5/t5/8l 5/20/81 "- 5/20/Bt 5/20/915/20/81 5/20/81 5/20/81. 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 , 5/20/81 5/'20/81 5/20/81 5/20/81 II Deal filiation: RaC 1 . Group, Re1c/o2vehrry. Time 303125 303126 II 1/2 hr. 303127 II 1/2 hr. 303128 II 2 hra. 303129 11 2 hra. 303130 303131 II 2 hra. III 1/2 hr. -^03t3t- --- -- -m-----ir/a-iitr-- --- 303133 III 1/2 hr. 303134 tit 2 hra. 303135 III 2 hfa. 303136 III 2 hra, 303137 303138 i303l39 303140 303141 303142 303143 'W1144 303145 III 8--h^rs, III 8 hra. III 8 hra. III 24 hrs. m lVl9. IlfkBll . in 24 hra. i 1/2 he. i 1/2 hr. i 1/2 hr. [ ^JB^H^L3-onAL GC Analyais (b) Date Analyzed 7/10/81.c 7/10/81.c 7/13/81.c 7/14/81,c 7/14/8X,c 7714/Bl.c 7/17/Sl.c ----.-- ICp l.UBF/ '' 16 5.4(c) 16 45 39 28 11 .. 7/U/81.C 7/17/Bl.c 7/13/81.p & 7/IS/81.C 7/13/61,p & 7/is/ai.c 7713/81.lit l/lS/Bl.c 77l0/81.p 7/10/81.p .-J^3......... 15 16 16 12 11 17 17 10 13 7/10/81.p 7/17/81,? 7/17/Sl.p 9.2 0.70 .7 7/17/81,p 1.5 7/17/81.C 21 7/17/ttl.c i&n0 7/l7/81,c 14 CONCENTRATION OF rEIll'HUUiiuui*nn". ... .-- Sample (n) PRAL No. 11-2135 81-2186 81-2187 81-2188 Date Received 5/20/81 5/20/81 5/20/81 5/20/81 81-2189 81-2190 5/20/01 5/20/81 81-2191 81-2192 81-2193 81-2053 81-2054 81-2055 81-2056 \ 81-2057 i 6 W 1 %(0 &. 0 0 ra 1.1 ^ 0 rf-* 0 0 3 ?. 3 -1 W 0 ' 0 S S7 28/81 5/20/81 5/20/81 5/15/01 5/15/81 5/15/81 5/15/81 5/15/81 Designation: Rat ff. Croup, Recovery Time 303U6 I 2 hrs. 303147 I 2 hrs. 303148 I 2 hra. 303149 I 8 hra. 303150 303151 I 8 hra. I 8 hrs. 30315^ - 3031J53 303154 Control fl Control fl Control (3 Control #4 Corittol t5 --t--24-hrr.- I 24 hra. I 24 hra. W ^ GC Analysis (b) v Date Analyzed 7/14/81,c 7/15/81,c 7/14/81,c 7/10/81,c & 7/10/81,p 7/10/81,p 7/10/81,c & 7/10/81.p ^mm.p 7/17/81,p [Cgl. URF/B 34 44 40 ^ >3 32 ^ " . ..... ..^.^...--.- 2.3 7/l7/8l,p 2.5 7/10/81p n.d. 7/10/81.p n.d. 7/17/81,p 7/17/81.p n.d. v-0.008 7/17/81,p \ n.d. TABLE 1 (a) Sample Designation foT|Bmfy)ral. All pregnant females, 25 ing/kg III, II, Group I, Group ^Group single dose &ix doses, 24 hours apart ten doses, 24 hours apart (b) GC determination of perfluorooctanoate as described in Lab Method ES-567 ("Determination of Perfluorooctanoic Acid in Blood, Gas Chromatographic Method", S. Stafford, 4/3/81), using perfluoro-n-oetanoic acid as calibration standard and either packed or capillary column analysis. (Type of analysis is indicated by p or e after the date). Results are reported as ppm F f<-r comparison with total organic fluorine analyses (ppa F 0.688 x ppn perfluorooctanoic acid), with a lower l^fflit for quantication of 0.007 ppn. Hone detected (n.d.) is reported for samples with ^ 0.005 ppm F, which cannot be distinguished from reagent background. Where the capillary column analysis was used the distribution of Cg isomers was also calculated, as described in the method, and the percentage of straight- " - is reported. Corresponding values for 1Q ppn standards are ^ 72S for ' ^ 94-952 forilBBBMBHlHBlBBHBKl Composition of the new lot lised for the inhalation studies (PBAL No. 81-2836. Haskell ^14045) able to that of other lots examined for Isomer distribution. (c) Approximate value, due to interference with the internal standard. Company Sanitized. Does r,.t contain TSCA CBl -22- TABLE 2 CONCENTRATION OF PERFLUUKUUUKWU.--I--U------frK-------------------------------------------------1^- INHALATION ^ ( a ) ^ - - Sample PRAL No. 81-2323 81-2329 81-2330 . 81-2327 81-2328 Date Received 5/28/81 5/28/81 5/28/81 5/28/81 S/28/81 Oesienation: Rat I, Group. Recovery Time 302207 (A) days (6-15) - 302302 (A) 302219 (A) days (6-15) days (6-15) - 303259 control 303260 control 31-2334 81-2335 81-2336 81-2337 81-2338 ^ 81-2339 V 81-23*0 81-2341 5/29/81 5/29/81 5/29/81 5/29/81 5/29/81 5/29/81 5/29/81 5/29/81 302197 302242 302284 302304 302335 302363 303261 303262 day 15, day 15, day 15, day 15, day 15. day 15, control control 2 hrs. 1/2 hr. 1/2 hr. 2 hrs. 2 hra. 1/2 hr. 0 0 =s << \ s Mr< CO Q. | u a 0 (a) (b) |H|l rH---- Sample Designation CorfU Inhalation ! 3 All pregnant females, 10 mg/tn . s indicated in the cable, exposure on days 6-15 of gestation or on day 15 only. GC analysis as described in Table 1, Note (b) 0 0 2. u 3 -0t) 0 ? 0 0 GC Analysis (b) \ Dace Analyzed 7/15/81,c 7/15/81.C 7/16/81,c 7/13/81,p [C^}. up F/fi 48 67 45 n.d. 7/13/81,p n.d. 7/16/81.C 7/l6/8lc- 7/16/81.C 7/16/81.C 7/16/81.C 7/l7/81,c 7/13/81.p 7/13/81.P 87 - --75 91 96 86 66 n.d. n.d. Recovery Time 1/2 hr. 2 hrs. 8 hrs. 24 hrs. RESULTS FOR Group I 25 mg/kg, single doa 2182 21 2183 18 2184 14 Avg. 18 PP" 2185 34 2186 44 2187 40 Avg. 39 ppa TABLE 3 I I Croup 25 nig/kg 6 doses 2047 16 2048 5.4 2049 16 Avg. 12 ppa 2050 45 2051 39 2052 28 Avg. 37 ppn 2188 33 2189 32 2190 29 Avg. 31 PP 2191 2.2 2192 2.3 2193 2.5 Avg. 2.3 PPB III Group 25 mg/kg 10 dosea_ 2170 11 2171 8.7 2172 15 Avg. 12 PPt 2173 16 2174 11 2175 17 Avg. 15 pp 2176 10 2177 13 2175 9.2 Avg. 11 PP" 2179 2180 2181 0.70 1.7 1.5 Avg. 1.3 PP"1 (b) Control 2053 2054 2055 2056 2057 n.d. n.d. n.d. ^.008 n.d. .GfB^Orala) ndJJ^B] "----a r----1 from Table 1, arranged by group and tine with averages by PRAL number. for each (a) Results set of three. Sample identification here is (b) Control samples for both1 -24- co^S^-00" I Table I column analyses,-in which the distribution along with for capillary axtd 4 branched isomers) is determined PRAL number. (a) Results from of Cg isomers (straight-chaiindentification here is by Sample the concentration. s , Company Sanitised. Does not contain TSCA CBI -25-  TABLE 5 COMCENTRATION 0 F PF.IlFLUOROOC'nftNOATF. IN IU\f BLOOD SAMI'JLESjBHjH.OKAL^ . ro w i ' 3, ^ 3. S "'. 3 5^ 0 > " Sample (a) PHAL No. 81-2122 81-2123 81-2124 81-2125 81-2126 81-2127 81-2120 81-2129 81-2130 81-2131 81-2132 31-2133 81-2134 81-2135 81-2136 81-2137 81-2138 31-2139 81-2140 81-21U 81-2142 81-2143 81-2144 DJItte Received 5/20/81 5/20/81 (c) 5/20/81 5/20/81 5/20/81 5/20/81 (c) 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 (c) 5/20/81 5/20/31 5/20/81 5/20/81 5/20/81 5/20/31 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 (c) 5/20/81 DOS iBnntion: Uat f, Group, Kecovery Time 303199 II 1/2 hr. 303200 II 1/2 hr. 303201 II 1/2 hr. 303202 II 2 hrs. 303303 II 2 hrs. 303204 II 2 hre. 303205 II 8 hrs. 303206 II 8 hrs. 303207 II 8 hrs. 303208 II 24 hrs. 303209 11 24 hrs. 303210 303211 303212 30321303214 303215 303216 303217 303218 303219 303220 II 24 hra. III 1/2 hr. III 1/2 hr. III 1/2 hr. III 2 hrs. III 2 hrs. III 2 hrs. III 8 hrs. III 8 hrs. III 8 hrs. 111 24 hrs. 303221 III 24 hrs. 81-21^5 5/20/81 303222 III 24 hrs. GC Analysis (b) \ Date Analyzed 7/27/81,c (d) 7/27/81,c (d) (d) (d) (d) (d) (d) 7/24/81,p (d) 7/24/81.p 7/29/81,c 7/29/81.C 7/29/81,c (d) (d) (d) 7/29/81,c 7/29/81,c 7/29/81,c (d) 7/29/81,c 7/30/81,p 7/27/ai.c 7/30/8l.p 1Cgl. HB ^.7 2.8 0.1 0.1 102 162 . 22 i 13 17 16 'v 20 15 15 Pr.RI'LUOnOOCTANOAITNE RAT ItToODSAMPLES CONCENTRATIONOF Sample (a) PRAL No. 81-2146 81-2147 81-2148 . 81-2149 81-2150 81-2151 81-2152 81-2153 Datbe Received 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/&1 81-2154 81-2155 0 ^ 1 "' 81-2156 01-2157 S < ^ f-. t-i . ^ 0 3 ^ 0 % tB. 3"*,i v> 0 > ^2, 81-2158 31-2159 81-2160 81-2161 81-2162 81-2163 81-2164 B1-2165 81-216b 81-2167 81-2168 81-2169 5/20/81 (c) 5'20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 Deaisnatton: 302494 302495 302496 303175 303176 303177 303178 303179 Bat JLj r.iroup, Retcovery Time IV 1/2 hr. IV 1/2 hr. IV 1/2 hr. I 1/4 hr. I 1/4 hr. I 1/4 hr. I 1/2 hr. 1 I 1/2 hr. 303180 303181 303182 303183 303184 303185 303186 303187 3 1-88 303189 303190 303191 303192 303193 303194 303195 i T T I I I I i i I I I T I T 1 1/2 hr. 1 hr. 1 hr. 1 hr. 2 hre. 2 hrs. 2 hrs. 4 hrs. 4 hrs. 4 hrs. 8 hre. 8 hra. Q hrs. 24 lira. 24 hrs. 24 hrs. GC Analysis (bl ,,.,,..,,>-..-. Dace Analyzed 7/21/81.C 7/21/81,c 7/21/81,c 7/24/81,c 7/27/81,c 7/27/81,c 7/21/Bl.c 7/21/81,c 7/21/81,p [C^il. ^8 F 23 28 17 8.5 16 16 16 v.13 Y.16 (d) 7/28/31.C 7/28/81.C 7/28/81,c 7/24/81.C 7/24/81.C 7/24/81,c 7/28/Bl.c 7/28/81.C 7/28/81,c 7/23/81.P 7/20/81.C 7/23/Bl.p 7/20/01.P 7/20/Bl.p 7/20/31.P 33 29 31 27 37 36 26 17 27 24 29 26 0 0 1i TABLE 5 CONCENTRATI UN rr riiivrijufnuuui..... Sample (a) PRAL No. 81-2281 Bl-2282 81-2283 81-2234 Date Received 5/22/81 5/22/81 5/22/81 5/22/81 81-2285 81-2286 .81-2288 . 81-2239 81-2290 81-2344 .' 81-2345 C& ^1 81-2346 "^ 81-2347 1p 81-2348 "1 %, 81-2349 ^ 81-2350 ^ 81-2351 % 81-2352 ^81-2353 % ?3l-2354 ^.1-2355 ^-2356 $-2357 5/22/81 5/22/81 5/26/81 5/26/81 5/26/81 5/29/81 5/29/81 5/29/81 5/29/81 5/29/81 5/29/81 5/29/31 5/29/81 5/29/81 5/29/81 5/29/81 5/29/81 5/29/81 5/29/81 DeaienaClon: Rat tf,i Croup, Recovery Time 302497 IV 3 hra. 302498 IV 8 hrs. 302499 IV 8 hrs. 302 SOO IV 24 hrs. 302501 302502 303196 303197 303198 303223 IV 24 hra. IV 24 hrs. I. - 168-hrA, I 168 hrs. I 163 hrs. V 1/4 hr. 303224 303225 303226 303227 303228 303229 303230 303231 303232 303233 303234 303235 303236 V 1/4 hr. V 1/2 hr. V 1/2 hr. V 1/2 hr. V 1/4 hr. V 2 hrs. V 2 hrs. V 2 hrs. V 4 hrs. V 4 hrs. V 4 hrs. V 8 hrs. V 8 hrs. C----3 GC Analysis (b) -------vL Hate Analyzed [C,,1. UK 7/23/81,c 7/23/81,c 7/23/8l,c 7/20/81,c 7/20781,p 7/22/81,c 7/2l/8l,c 7/2l/AlP 7/21/71,p 7/16/81,p 7/30/81,p 7/30/81.C 7/30/81,c 7/20/81.C 7/20/81,c 7/20/81,c 7/30/81,c 62 62 66 51 M8 45 53 -A.DS 0.03 0.05 ~ 9.5 . 9.8 24 29 22 .' 25 18 (d) (d) (d) (d) (d) (d) 7/30/81,p 8. 7/20/81,c M4 7/20/31.p 13 Sample (at PKAL No. 81-2358 81-2359 81-2360 81-2361 81-2362 81-2363 01-2360 81-2550 81-2551 i 81-2552 M VD 1 A CONCENTRATIONOF PERFLUOROOCTANOAITNE RAT BLOCTffiAHPLES. Date Received 5/29/81 5/29/81 5/29/B1 5/29/81 5/29/81 5/29/81 5/29/81 6/4/81 6/4/81 6/4/81 Designation: Rat fi Ir.roup, R ecovery Time 303237 V 8 hrs. 303238 303239 303240 302503 V 24 hra. V 24 hrs. V 24 hra. IV 168 hrs. 302504 302505 IV ----... ---,.---- IV 168 hrs. 168 hra. 303241 303242 303243 V 168 hrs. V 168 hrs. V 168 hra. GC Analysis (b) ------^------ Dace Analyzed ICp^ UK F/fi b 7/20/81.C ~15 7/20/81,p 18 7/16/81,p 0.80 7/20/81,p 0.81 7/16/Ol.p 0.67 7/21/Bl.p 7/22/81.c 7/21/ai.p . -- -T/ir/ar.c"' 7/21/Bl.p 7/22/81,c 16 16 AItZ1B0 ...... ^ . j'kx1213 26 ...... 7/27/Bl.p 7/27 & 7/31/81.P 0.12 0.12 7/27 fr 7/31/81,p O.OS8 1 natoMta (WWOSanW^.0"" TABLE 5 Eorj----------^1 (a) Sample Designation (b) (c) (d) (e) III, 25 mg/kg, s-.iin--gile doa* Group Group X; females, II; females, 2.5 mg/kg, mg/kg, single dose single dose ""Group females 150 jsingle dose Group IV; males, 25 mg/kg, 11 doses 24 hours apart Group V; females, 25 ag/kg, " w >100 ppn have been as described in TabfLtt I. Note (b). Values averages, etc., but should be standard GC Analysis reported to 3 figures for calculation of (consistent with the 101 relative rounded to 2 significant figure? deviation of the method). inhomoganeous before aliquots could which had coagulated and become lyophilized, however, and can be Samples be taken. The entire volume has been analyzed if necessary. at this time, but have been dried for Samples which have not been analyzed conditions as the others. storage under the same with the internal standard in the packed column Approximate values, due to interference but Large isoner contribution by in the peak height only. caanpaliyllsairsy. coBleusmtn easntiamlyasteis,is packed column, calculated i S.nllU.d.""^"0'"'"'"1'60*0" Company Sannizec -30- ^mo3.^ ^co"1n3^1"nTSC^ Recovery Time 24 hrs. 168 hra. Group I 25 nf,/t(B single dose, female 2167 0.57 2168 0.45 2169 1.2 Avg. 0.74 ppm 2238 0.052 2289 0.033 2290 0.051 Avg. .045 ppm TABLE 6 RESULTS FOJ ' Group II 2.5 mg/kg single dose, female 2131 0.13 2132 (c) 2l!33 0.11 Avg. 0.12 ppm III Group 150 ing/he single done, female 2143 2144 2145 Avg. (c> 20 15 18 ppm Group IV ""2S ^ m'"Ha"/kf0i single dose, male 2284 51 2235 45 2286 51 Avu. 50 ppn 2362 16 2363 29 2368 26 Avg. 24 ppn v \ Group V 25 in 11 d fema 2359 2360 2361 Avg. 2550 2551 2552 Avg. .^^Oral)^^--------f by group and time with averages for each set of three. Saaple (a) Result.!,, from Table 5, arranged > 100 should be rounded co two significant figures* As noted there, values Identification is by PRAL number. "--------Lrt--ix n<f------Hi (b) The control group in Table 3 applied to bothi (c) Samples dried but not analyzed at this time. San'sfissd. Doss nol contain ppjnpany' RESULTSFOR] TABLE 7 PERCENT STRAIGHT-CHAIN 0, (a) Group V ----25 ng/k ^ ^ ^ Sanitt^01"'" CoffiP3^ RESULTS FOJR, TABLE 7 ^^ PERCENT STRAIGHT-CHAIN C^ (a^ Recovery Time Group I 25 mr./kR III Group 11 Group Group IV Gr 2.5 TOR/kg 150 mg/kg 25 mg/kg sinp.le dose, Bingle doae single dose single dose female female female male 24 hrs. 2167 2168 2169 - 2131 - 2143 (c) 2284 77 2 2132 (c) 2144 94 2285 77 2 2133 - 2145 91 22B& 76 2 Avg. " Avg. 77X 16B hrs. 2288 - -- 2362 94 2 22B9 - 2363 63 2 2290 - 2368 M 2 Avg. 87X (a) Results from Table 5 for capillary column analyses, in which the distribution of Cg isomere (straight-chain and 4 branched isoiners) is determined along with the concentration. Sample Identification is by PRAL number. Company SanWzod. Do CONCENTRATIONOF TAULb ^1 .^k.i& PERFi.UOROOCTANOAINTERAT BLOOD SAMPLES. GC Annlvaia (b) Sample (a) PRAL No. Date Received 81-2295 5/27/81 01-2296 5/27/81 81-2297 5/27/81 . 81-2298 5/27/81 81-2299 5/27/81 81-2300 81-2301 81-2302 5/27/81 5/27/81 ...... 5/27/81 81-2303 5/27/81 81-2304 5/27/81 81-2305 5/27/81 i 81-2324 ^ 81-2325 81-2326 5/28/81 5/20/81 5/28/81 81-2443 6/2/81 81-2444 6/2/81 81-2445 6/2/81 81-2446 6/2/81 81-2447 81-2448 81-2449 81-2450 6/2/31 6/2/81 6/2/81 6/2/81 31-2451 6/2/81 81-2452 6/2/81 81-2453 6/2/81 DeslRnatlon: Rat I, Croup. Recovery Time 303245 II 1/2 tu. 303246 II 1/2 hr. 303247 . II 1/2 hr. 303248 11 2 hrs. 303249 II 2 hre. 303250 II 2 hra. 303251 11 8 hrs. 303252 303253 II 8 hrs. II 8 hra. 303257 control 303258 303254 303255 303256 control 11 II II 24 hra. 24 hra. 24 hra. 303273 control 303274 control 303275 303277 303278 303279 303280 303281 303282 303283 303285 control III Ill Ill Ill Ill HI Ill Ill 1/2 hr. 2 hrs. 1/2 hr. 1/2 hr. 2 hrs. 2 hrs. 8 hrs. 8 hrs. Date Analyzed ICg] . UR 8/3/Bl.p 1.8 8/3/81,p 2.2 8/3/8l,p 1.4 8/6/Bl.p 2.2 8/6/Bl.p 1.5 8/6/Bl.p 8/6/81,p TO7BI.P 2.1 0.79 -0:99 8/6/81.p 0.7 7/27/Bl.p n.d 7/27/Bl.p n.d 7/24/Bl.p 0.1 7/24/8l,p 0.1 7/24/81.p 0,1 8/4/81,p . 0. 8/4/8l,p 0. 8/4/81,p 0. 8/5/81,p 9 0/6/81,p 9 8/5/81,p 6 a/5/81,p 6 8/6/81.P 2 8/6/8l,p 8/5/81.P B/5/81.P Company s^.--'"" Sample (a) PRAL No. 81-245A 31-2455 81-2456 . 81-2457 81-2458 81-2459 81-2460 81-2461 81-2462 81-2463 81-2464 81-2465 <L 81-2466 <t\ ' 81-2467 81-2468 01-2469 01-2470 81-2471 81-2472 81-2497 81-2498 01-2499 81-2500 81-2501 81-2502 D ate Recelv ed 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/3/81 6/3/81 6/3/81 6/3/81 6/3/81 6/3/81 Designation: 303286 303289 303290 303291 303292 303293 303294 303295 303296 303297 303298 303299 303300 303301 303302 303303 303304 303305 303306 303284 303287 303288 303307 303309 303310 Rat: ff , Group, III I I I I I I I - ........ 1 I I I I I I I I I I III III III I I I Recovery Tl-ae 8 hra. 1/4 hr. 1/4 hr. 1/4 hr. 1 hr. 1/2 hr. 1/2 hr. 1/2-lHE. 2 hra. 1 hr. 1 hr. 2 hra. 2 hra. 4 hra. 4 hrs. 4 hrs. 8 hrs. 8 hra. 8 hrs. 24 hra. 24 hrs. 24 hra. 24 hra. 24 hra. 24 hrs. INHALATION c----j CC Analysis (b) -------->; Date Analyzed 8/5/81,p [Cfil. P6 V 3.9 8/12/Bl.c 80 8/12/Sl.c 88 8/12/81,c 121 8/11/81,c 104 8/5/31,c 111 8/5/81.C 93 fl^/SlYC 124 8/6/81,c 79 0/11/81,c 121 8/12/81,c 115 8/6/81.c 50 8/6/81,c 78 8/10/81,c 77 8/11/81.c 69 8/11/81,c '60 8/10/81.c 60 8/10/81,c 43 8/10/81.C 111 7/31/81.p 0.64 7/3l/8l,p 0.79 7/31/fll.p 0.24 8/3/81.C 68 8/3/81.c 42 8/3/81.C 46 Company Sanded. Docs not c PERFl.UOROOCTANOAINTERAT BLOOD SAMPLES CONCENTRATIONOF INHALATION Sample (a) PRAL No. Date Received 81-2503 6/3/81 81-2504 6/3/81 81-2505 6/3/81 81-2506 6/3/81 81-2507 6/3/81 81-2508 6/3/81 81-2509 6/3/81 81-2510 6/3/81 81-2511 6/3/81 81-2512 6/3/81 81-2513 6/3/81 i 81-2523 ii ~ 81-2524 l 81-2525 6/4/81 6/4/81 6/4/81 81-2526 6/4/81 81-2527 6/4/81 81-2594 6/9/81 81-2595 6/9/81 81-2596 6/9/81 81-2597 6/9/81 81-2598 6/9/81 Deal gnat ton; Rat 0, Croup, Rec overy Time 303794 control 303795 303796 303797 303798 303799 303810 303011 303812 303813 303816 control IV IV IV IV IV IV IY IV IV 1/2 hr. 2 hrs. 1/2 hr. 1/2 hr. 2 hrs. 2 hrs. 8 hra. 8 hra. 8 hrs. 303908 control 303909 303817 303818 303819 303308 303311 303312 control IV IV IV I I I 24 hra. 24 hra. 24 hra. 168 hrs. 168 hrs. 168 hrs. 303263 control 303261 control CC Analysis |DJ A---- \ Date Analyzed 8/4/ai,p 8/4/81,p 8/6/81,c 8/7/81,c 8/7/81,p 8/7/81.C 8/7/Bl.c 8/7/81,c 8/12/81.C B/13/81,c 8/13/81,c |CQ\. UK P/B 0.19 (c) 0.11 118 153 131 163 203 114 177 198 170 8/6/81.p n.d. 8/6/81.P 8/6/81,c 8/6/81,c 8/6/81.C n.d. 143 ^148 151 7/27/81.p 7/27/81.p 7/27/81.p 1.1 0.54 0.51 8/7/81,p n.d. 8/7/81.P n.d. Company Sanitized. Does TABLE 8 (a) Sample Designation ^llllBJl Inhalation III; Group Group Group ""Group I; females, 10 mg/a - II; females, 0.1 mg/is , females, 1.0 mg/a IV; males, 10 g/m^ (b) GC Analysis as described in Table 1, Note (b). Values >100 ppm have been reported to 3 figures for calcqlation of averages, etc., but should be rounded to 2 significant figures (consistent with the 102 relative standard deviation of the method). (c) An unusually high percentage of branched isooers (similar co)|------A was observed in this sample compared to others of similar cofeentracion; result was calculated by peak height only (rather than height and area). Company Sanded. Does not contain TSCA CBJ -38- TABLE 9 Recovery Time 1/4 hr. 1/2 hr. 1 hr. 2 hrs. 4 hrs. | Group I 3 10 ing/in , female i GroiiD II 0.1 mg/m female 2455 80 - 2456 88 2457 121 Avg. 96 ppm 2459 111 2460 93 2461 124 Avg. 109 ppm 2295 1.8 2296 2.2 2297 1.4 Avg. 1.8 ppm 2463 121 2464 115 2458 104 Avg. 113 ppm 2462 79 2465 50 2466 78 Avg. 69 ppm 2298 2.2 2299 1.5 2300 2.1 Avg. 1.9 ppm 2467 77 2468 69 2469 60 AVR. 69 ppm III Group ----i----------y1.0 mg/ro female - 2446 9.4 2448 6.0 2449 6.9 Avg. 7.4 ppm 2447 9.7 2450 24 2451 18 Avg. 17 ppm Group IV 10 rog/m^ male - 2505 118 2507 131 2508 163 Avg. 137 ppn 2506 153 2509 203 2510 114 Avg. 157 ppm \ Control 2304 n 2305 n 2443 0 2444 0 2445 0 2503 0 2504 0 A25p Zfk3A n 2524 n 2597 n 2598 n I cowaiiy3, "",',-,'-.,. DO-."'"- Recovery Time 8 hrs. Group I 10 mg/ro , female 2470 60 2471 43 2472 111 Avg. 71 ppm TABLE 9 RESULTS FORJ ^ (a) Group 11 J--~ ^ 0.1 mg/m female 2301 2302 2303 0.79 0.99 0.76 Avg. 0.85 ppm Group III 1.0 ros/ni* female 2452 6.1 2453 2.b 2454 3.9 Avg. 4.2 ppm Group IV ----1:-------- 10 nig/re male 2511 177 2512 198 2513 170 Avg. 182 ppo Con 24 hra. 2500 68 2501 42 2502 46 Avg. 52 ppm 2324 2325 2326 0.15 0.10 0.16 Avg. 0.14 ppm 2497 2498 2499 0.64 0.79 0.24 Avg. 0.56 ppm 2525 143 2526 148 2527 151 Avg. 147 ppm 168 hra. 2594 2595 2596 0.11 0.54 0.51 Avg. 0.39 ppm (a) Results froi.i Table 8, arranged by firoi and time with averages for each set of three. As not there, values > 100 should be rounded to two significant figures. Sample identification is b . ^ ^ ^ s ,,-,;% sa"-'-- Recovery Time 1/4 hr. 1/2 hr. 1 hr. 2 hrs. 4 hrs. 8 hrs. Group I 10 iiiR/m , female 2455 91 2456 92 2457 91. Avg. 91X 2459 90 2460 89 1461 91 Avg. 90X 2463 86 2464 86 2458. 81 Avg. 87X 2462 91 2465 93 2466 92 ' Avg. 92X 2467 95 2468 93 2469 92^ Avg. 93X 2470 90 2471 92 2472 91 Avg. 91X Group II 0.1 ing/in female TABLE 10 PERCENT STRAIGHT-CHAIN ,, (a) Group III 1.0 mg/m3 female Group IV -----i----------- 10 rog/m male -. - - 2295 2296 2297 - -- 2446 90 2448 86 2449 89 Avg. 88X -- 2505 76 2507 76 2508 75 Avg. 76X -- Cont 81-2 -2 -2 -2 -2 -2 -2 -2 -2 "2 -2 2298 2299 2300 - -- 2447 2450 2451 - -- 2506 76 2509 77 2510 75 Avg. 76X -- 2301 2302 2303 - 2452 2453 2454 - 2511 80 2512 79 2513 71 Avg. 79X M Corn?^5801^0^-.Ooes"0 Recovery Time 24 hrs. 168 hrs. Group 1 ------,-.,,.,^...., 10 rog/m , female 2500 89 2501 90 2502 88 Avg. 88X 2594 - 2595-- 2596 - TABLE 1 PERCENT STRAIGHT-CHAIN C. (a) I I Group ------------3-- 0.1 mR/rn female III Group 1.0 rog/m-* female Group IV 10 ing/in1 male 2324 2325 2326 - 2497 2498 95 2499 - 2525 83 2526 80 2527 82^ Avg. B2Z - - - Con (a) Results from Table 8 for capillary column analyses. In which the distribution of Cg isoreera (straight-chain and 4 branchedllsomers) Is deternihed along with the concentration. Saiaple identification is by PRAL number. , al Cornpa1^ s^^.0065"0'"